RECRUITINGINTERVENTIONAL
Pilot Study of Open Label Homocysteine Management Therapy in Levodopa-treated Parkinson's Disease
About This Trial
This is a research study investigating elevated homocysteine in the blood of patients with Parkinson's disease who are currently receiving treatment with levodopa. We are evaluating if elevated homocysteine can be corrected using open label B vitamin therapy, as well as the impact of homocysteine levels on cognitive function.
Who May Be Eligible (Plain English)
Who May Qualify:
1. Diagnosis of probable Parkinson's Disease according to Movement Disorders Society criteria.
2. Currently treated with levodopa at a minimum dose of 300 mg/day
3. Montreal Cognitive Assessment (MOCA) ≥15
4. Demonstrated capacity to provide willing to sign a consent form.
5. 40-90 years of age
6. Estimated glomerular filtration rate ≥60
7. Absence of uncontrolled hypertension in medical history
8. Absence of insulin use
Who Should NOT Join This Trial:
\-
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
1. Diagnosis of probable Parkinson's Disease according to Movement Disorders Society criteria.
2. Currently treated with levodopa at a minimum dose of 300 mg/day
3. Montreal Cognitive Assessment (MOCA) ≥15
4. Demonstrated capacity to provide informed consent.
5. 40-90 years of age
6. Estimated glomerular filtration rate ≥60
7. Absence of uncontrolled hypertension in medical history
8. Absence of insulin use
Exclusion Criteria:
\-
Treatments Being Tested
DIETARY_SUPPLEMENT
Folic Acid 1 MG
Folic Acid 1mg per day
DIETARY_SUPPLEMENT
Vitamin B6 25 MG
Vitamin B6, 25mg per day
DIETARY_SUPPLEMENT
Vitamin B12
Vitamin B12, 1,000 ug per day
Locations (1)
Oregon Health & Science University (OHSU)
Portland, Oregon, United States